Skip to main content
. 2021 Aug 25;49(8):03000605211038135. doi: 10.1177/03000605211038135

Figure 2.

Figure 2.

Risk of bias in the studies included in the meta-analysis of the efficacy and safety of daratumumab in the treatment of multiple myeloma.